515 related articles for article (PubMed ID: 33166580)
1. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.
Fernández-Juárez G; Rojas-Rivera J; Logt AV; Justino J; Sevillano A; Caravaca-Fontán F; Ávila A; Rabasco C; Cabello V; Varela A; Díez M; Martín-Reyes G; Diezhandino MG; Quintana LF; Agraz I; Gómez-Martino JR; Cao M; Rodríguez-Moreno A; Rivas B; Galeano C; Bonet J; Romera A; Shabaka A; Plaisier E; Espinosa M; Egido J; Segarra A; Lambeau G; Ronco P; Wetzels J; Praga M;
Kidney Int; 2021 Apr; 99(4):986-998. PubMed ID: 33166580
[TBL] [Abstract][Full Text] [Related]
2. The STARMEN trial: rethinking calcineurin inhibitor therapy in membranous nephropathy.
Floege J; Rovin BH
Kidney Int; 2021 Apr; 99(4):811-813. PubMed ID: 33745547
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS
Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759
[TBL] [Abstract][Full Text] [Related]
4. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
[TBL] [Abstract][Full Text] [Related]
5. Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy.
Rojas-Rivera J; Fervenza FC; Ortiz A
Drugs; 2022 Feb; 82(2):109-132. PubMed ID: 34932208
[TBL] [Abstract][Full Text] [Related]
6. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.
van den Brand JAJG; Ruggenenti P; Chianca A; Hofstra JM; Perna A; Ruggiero B; Wetzels JFM; Remuzzi G
J Am Soc Nephrol; 2017 Sep; 28(9):2729-2737. PubMed ID: 28487395
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tacrolimus monotherapy versus cyclophosphamide-corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis.
Gong L; Xu M; Xu W; Tang W; Lu J; Jiang W; Xie F; Ding L; Qian X
Medicine (Baltimore); 2021 Jul; 100(28):e26628. PubMed ID: 34260552
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial.
Xu J; Zhang W; Xu Y; Shen P; Ren H; Wang W; Li X; Pan X; Chen N
Contrib Nephrol; 2013; 181():152-62. PubMed ID: 23689577
[TBL] [Abstract][Full Text] [Related]
9. Multitarget therapy with a corticosteroid, cyclosporine and mycophenolate mofetil for idiopathic membranous nephropathy: a prospective randomized controlled trial.
Duan Y; Bai Y; Guo W; Wang L; Dai W; Guo W; Huang H; Liu W; Diao Z
Nephrol Dial Transplant; 2023 Dec; 39(1):95-102. PubMed ID: 37437905
[TBL] [Abstract][Full Text] [Related]
10. Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial.
Scolari F; Delbarba E; Santoro D; Gesualdo L; Pani A; Dallera N; Mani LY; Santostefano M; Feriozzi S; Quaglia M; Boscutti G; Ferrantelli A; Marcantoni C; Passerini P; Magistroni R; Alberici F; Ghiggeri GM; Ponticelli C; Ravani P;
J Am Soc Nephrol; 2021 Apr; 32(4):972-982. PubMed ID: 33649098
[TBL] [Abstract][Full Text] [Related]
11. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
Fervenza FC; Appel GB; Barbour SJ; Rovin BH; Lafayette RA; Aslam N; Jefferson JA; Gipson PE; Rizk DV; Sedor JR; Simon JF; McCarthy ET; Brenchley P; Sethi S; Avila-Casado C; Beanlands H; Lieske JC; Philibert D; Li T; Thomas LF; Green DF; Juncos LA; Beara-Lasic L; Blumenthal SS; Sussman AN; Erickson SB; Hladunewich M; Canetta PA; Hebert LA; Leung N; Radhakrishnan J; Reich HN; Parikh SV; Gipson DS; Lee DK; da Costa BR; Jüni P; Cattran DC;
N Engl J Med; 2019 Jul; 381(1):36-46. PubMed ID: 31269364
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy and safety of tacrolimus monotherapy and cyclophosphamide combined with glucocorticoid in the treatment of adult primary membranous nephropathy: protocol of a multicenter, randomized, controlled, open study.
Chen S; Ren S; Wang AY; Tran H; Li Z; Cheng X; Liu M; Li G; Wang L; Hong D
Trials; 2020 Feb; 21(1):219. PubMed ID: 32093742
[TBL] [Abstract][Full Text] [Related]
13. A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study.
Rojas-Rivera J; Fernández-Juárez G; Ortiz A; Hofstra J; Gesualdo L; Tesar V; Wetzels J; Segarra A; Egido J; Praga M
Clin Kidney J; 2015 Oct; 8(5):503-10. PubMed ID: 26413273
[TBL] [Abstract][Full Text] [Related]
14. Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial.
Scolari F; Dallera N; Gesualdo L; Santoro D; Pani A; Santostefano M; Feriozzi S; Mani LY; Boscutti G; Messa P; Magistroni R; Quaglia M; Ponticelli C; Ravani P
BMJ Open; 2019 Dec; 9(12):e029232. PubMed ID: 31806605
[TBL] [Abstract][Full Text] [Related]
15. Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New-incident and relapsing primary membranous nephropathy.
Kanigicherla DAK; Hamilton P; Czapla K; Brenchley PE
Nephrology (Carlton); 2018 Jan; 23(1):60-68. PubMed ID: 27778424
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.
Cortazar FB; Leaf DE; Owens CT; Laliberte K; Pendergraft WF; Niles JL
BMC Nephrol; 2017 Feb; 18(1):44. PubMed ID: 28143416
[TBL] [Abstract][Full Text] [Related]
17. [Membranous nephropathy: New insights in therapeutic approach].
Dahan K
Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tacrolimus monotherapy versus tacrolimus-corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis.
Gong L; Xu M; Xu W; Tang W; Lu J; Jiang W; Xie F; Ding L; Qian X
Medicine (Baltimore); 2021 Dec; 100(51):e28225. PubMed ID: 34941086
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis.
Chen M; Zhang X; Xiong Y; Xu G
Int Urol Nephrol; 2023 Mar; 55(3):641-651. PubMed ID: 36161550
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study.
Zhang S; Huang J; Dong J; Li Z; Sun M; Sun Y; Chen B
Front Immunol; 2023; 14():1156470. PubMed ID: 37187749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
